ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer …
WEB5 days ago · Resize. By Don Nico Forbes. Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first ...
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
WEB4 days ago · GSK and iTeos Therapeutics revealed data Saturday from the Phase II GALAXIES Lung-201 platform Phase II study, showing that Jemperli and the investigational anti-TIGIT therapy belrestotug elicited promising response rates in patients with non-small cell lung cancer. After at least 5.6 months of follow-up, …
Buy Rating Affirmed for iTeos Therapeutics Amid Promising Lung …
WEB6 days ago · Eva Fortea Verdejo, an analyst from Wells Fargo, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The associated price target remains the same with $31.00. The ...
TIGIT drug from iTeos shrinks lung tumors in trial - Yahoo Finance
WEB6 days ago · The results, from a mid-stage clinical trial, show that adding iTeos’ drug to an approved GSK immunotherapy shrank lung tumors in roughly twice as many people as GSK’s therapy alone. They have ...
iTeos Therapeutics, Inc. (ITOS) Latest Stock News & Headlines
WEBGet the latest iTeos Therapeutics, Inc. (ITOS) stock news and headlines to help you in your trading and investing decisions.
iTeos Therapeutics | iTeos Therapeutics Announces Late-Breaking …
WEBAug 20, 2024 · WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos ...
ITeos Therapeutics Shares Rise on Positive Data From Lung
WEB4 days ago · Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung ...
iTeos Therapeutics Announces $120 Million Registered Direct …
WEBMay 10, 2024 · iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics...
iTeos Reports First Quarter 2023 Financial Results and Provides ...
WEBMay 10, 2023 · iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates. May 10, 2023. PDF Version. – Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens.
View from ESMO: iTeos data keep TIGIT alive, for now
WEB3 days ago · September 18, 2024 12:55 AM UTC. iTeos has delivered another Phase II win for cancer immunotherapy target TIGIT, but with the readout comes some of the same questions and concerns that have contributed to the mechanism’s past failures to translate to Phase III success. iTeos Therapeutics Inc. (NASDAQ:ITOS) reported at …
Skip to content